Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: clinicopathologic features and survival data. Poster presented at the 2011 ASCO Annual Meeting; June 2011. [abstract] J Clin Oncol. 2011 May 20; 29(Suppl 15):4123. doi: 10.1200/jco.2011.29.15_suppl.4123
Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microrna to predict the tissue of origin (ToO) in patients with cancer of unknown primary (CUP). Poster presented at the 2010 ASCO meeting; May 2010. [abstract] J Clin Oncol. 2010 May; 28(Suppl 15).
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 Feb 20;26(6):925-33.
Fleming AD, Philip S, Goatman KA, Williams GJ, Olson JA, Sharp PF. Automated detection of exudates for diabetic retinopathy screening. Phys Med Biol. 2007 Dec 21;52(24):7385-96. doi: 10.1088/0031-9155/52/24/012
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Fleming AD, Goatman KA, Philip S, Olson JA, Sharp PF. Automatic detection of retinal anatomy to assist diabetic retinopathy screening. Phys Med Biol. 2007 Jan 21;52(2):331-45. doi: 10.1088/0031-9155/52/2/002
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.
Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, BerchucK A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75.
Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.
Smith T, Hillner B, Neighbors DM, McSorley P, LeChevalier T. An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol. 1995;13(9):2166-73. doi: 10.1200/JCO.1995.13.9.2166.